Parkman Healthcare Partners LLC Buys Shares of 1,807,621 Xeris Biopharma Holdings, Inc. $XERS

Parkman Healthcare Partners LLC bought a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,807,621 shares of the company’s stock, valued at approximately $14,316,000. Xeris Biopharma comprises 1.5% of Parkman Healthcare Partners LLC’s investment portfolio, making the stock its 29th largest position. Parkman Healthcare Partners LLC owned approximately 0.99% of Xeris Biopharma as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Xeris Biopharma during the second quarter valued at $115,042,000. Vanguard Group Inc. boosted its holdings in Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after acquiring an additional 1,358,760 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Xeris Biopharma by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after acquiring an additional 135,815 shares during the last quarter. State Street Corp grew its stake in shares of Xeris Biopharma by 10.1% in the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after acquiring an additional 378,595 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its holdings in shares of Xeris Biopharma by 6.0% during the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after acquiring an additional 185,063 shares in the last quarter. 42.75% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the sale, the director owned 126,500 shares of the company’s stock, valued at $770,385. This trade represents a 11.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00. Following the sale, the insider directly owned 1,361,053 shares in the company, valued at approximately $11,568,950.50. The trade was a 0.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 271,499 shares of company stock worth $2,038,917 in the last three months. 4.35% of the stock is currently owned by company insiders.

Xeris Biopharma Stock Performance

Shares of XERS opened at $8.74 on Tuesday. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -79.45 and a beta of 0.66. The business’s fifty day simple moving average is $8.15 and its two-hundred day simple moving average is $6.88. Xeris Biopharma Holdings, Inc. has a 12 month low of $5.25 and a 12 month high of $10.08. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The business had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

XERS has been the subject of several recent analyst reports. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Barclays increased their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Wall Street Zen cut shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $12.00.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.